TuHURA Biosciences (NASDAQ:HURA) Upgraded by Wall Street Zen to Hold Rating

TuHURA Biosciences (NASDAQ:HURA) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Monday.

Several other equities research analysts also recently weighed in on HURA. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of TuHURA Biosciences in a research report on Tuesday, February 3rd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, TuHURA Biosciences has a consensus rating of “Hold” and an average price target of $9.00.

TuHURA Biosciences Stock Performance

Shares of HURA opened at $1.81 on Monday. The stock has a market capitalization of $109.90 million, a PE ratio of -3.62 and a beta of -0.33. TuHURA Biosciences has a 1 year low of $0.41 and a 1 year high of $4.44. The company’s 50-day simple moving average is $1.30 and its 200-day simple moving average is $1.65.

Institutional Trading of TuHURA Biosciences

A number of institutional investors have recently bought and sold shares of HURA. Virtu Financial LLC acquired a new stake in shares of TuHURA Biosciences during the 3rd quarter worth about $26,000. JPMorgan Chase & Co. acquired a new position in TuHURA Biosciences in the second quarter valued at approximately $27,000. Intech Investment Management LLC acquired a new position in TuHURA Biosciences in the second quarter valued at approximately $29,000. Wells Fargo & Company MN increased its stake in TuHURA Biosciences by 109.0% in the fourth quarter. Wells Fargo & Company MN now owns 38,208 shares of the company’s stock valued at $29,000 after purchasing an additional 19,931 shares during the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in TuHURA Biosciences during the fourth quarter worth approximately $30,000. 0.62% of the stock is owned by hedge funds and other institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.